Kirubel Tefera, MD
Hematology & Oncology · Cincinnati, OHNPI 1558523977
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $998, more than ten times the $18 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 104 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$298
- AstraZeneca$291
- E.r. Squibb & Sons, L.L.C.$261
- Merck$199
- AVEO Pharmaceuticals, Inc.$162
- Exelixis Inc.$160
- plus $1K from 31 others
Across 3 payments — averaging $126,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$380K
What the payments were for
- Food & beverage$2,66499%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $298 |
| AstraZeneca(2 entities) | 8 | $291 |
| E.r. Squibb & Sons, L.L.C. | 3 | $261 |
| Merck | 9 | $199 |
| AVEO Pharmaceuticals, Inc. | 7 | $162 |
| Exelixis Inc. | 1 | $160 |
| GSK | 5 | $100 |
| Pfizer | 4 | $93 |
| Incyte Corporation | 4 | $92 |
| AbbVie | 3 | $89 |
| Astellas Pharma US Inc | 4 | $86 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Geron Corporation | 2 | $52 |
| Azurity Pharmaceuticals, Inc. | 2 | $52 |
| Sanofi | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Eisai Inc. | 2 | $46 |
| Johnson & Johnson(2 entities) | 3 | $45 |
| Seagen Inc. | 2 | $44 |
| Array Biopharma Inc | 2 | $40 |
| Amgen | 3 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Tersera Therapeutics LLC | 1 | $38 |
| Genentech USA, Inc. | 2 | $34 |
| Gilead | 1 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Sandoz | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Immunocore Limited | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,684 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 17 | $431,123 |
| ImbruvicaIbrutinib | 26 | $411,593 |
| RevlimidLenalidomide | 26 | $411,242 |
| LenvimaLenvatinib Mesylate | 16 | $377,358 |
| NubeqaDarolutamide | 21 | $238,450 |
| XermeloTelotristat Etiprate | 14 | $136,405 |
| OrgovyxRelugolix | 14 | $35,858 |
| EliquisApixaban | 42 | $33,585 |
| Abiraterone Acetate | 31 | $32,870 |
| XareltoRivaroxaban | 37 | $28,860 |
| Prochlorperazine Maleate | 87 | $1,826 |
| Dexamethasone | 81 | $1,532 |
| Ondansetron Hcl | 17 | $725 |
| Hydroxyurea | 34 | $526 |
| Acyclovir | 28 | $507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $160 | $431,12317 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $30 | $411,59326 claims |
| Eisai Inc.Lenvima | $46 | $377,35816 claims |
| BayerNubeqa | $18 | $238,45021 claims |
| Tersera Therapeutics LLCXermelo | $38 | $136,40514 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $38 | $35,85814 claims |
| PfizerEliquis | $93 | $33,58542 claims |
| Johnson & JohnsonXarelto | $45 | $28,86037 claims |
| Lilly USA, LLCOlanzapine | $20 | $35924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.